Squamous Cell Esophageal Carcinoma
Conditions
Interventions
Experimental Group:Neo-adjuvant Chemoradiotherapy followed by Surgery
Sponsors
Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients are eligible to be included in the study only if they meet all of the following criteria: 1. Histologic diagnosis of squamous cell thoracic esophageal carcinoma of Stage IIB or III, which is potentially resectable; 2. Patients must not have received any prior anticancer therapy; 3. More than 6 months of expected survival; 4. Age ranges from 18 to 60 years.5. Absolute white blood cells count >=4.0*10^9/L, neutrophil >=1.5*10^9/L, platelets >=100.0*10^9/L, hemoglobin >=90g/L, and normal functions of liver and kidney; 6. Karnofsky performance status more than 90; 7. Signed informed consent document on file.
Exclusion criteria
Exclusion criteria: 1. Patients are diagnosed or suspected to be allergic to cisplatin or vinorelbine; 2. Patients with concomitant hemorrhagic disease; 3. Pregnant or breast feeding; 4. Inability to use gastric conduit after esophagectomy because of a prior surgery; 5. Patients with concomitant peripheral neuropathy, whose CTC status is 2 or even more; 6. Have a prior malignancy other than esophageal carcinoma, carcinoma in situ of the cervix, nonmelanoma skin cancer or cured early stage of prostate cancer.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Disease free survival tim; | — |
Primary
| Measure | Time frame |
|---|---|
| Survival rate;Survival time; | — |
Countries
China
Contacts
Public ContactJian-hua Fu, Meng-zhong Liu
Outcome results
None listed